Fulgent Genetics, Inc. (FLGT) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Fulgent Genetics operates two primary segments: Laboratory Services (diagnostic testing and pathology) and Therapeutic Development (cancer drug candidates). During the quarter, the Company completed the acquisition of Bako Diagnostics and StrataDx (the "Bako Acquisition") on March 17, 2026, to expand its laboratory services capabilities. The Company is also advancing its therapeutic pipeline, specifically the Phase 2 study of FID-007 for head and neck squamous cell carcinoma.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $85.4 million | $81.8 million | $156.5 million | $155.3 million |
| Gross Profit | $25.7 million | $34.4 million | $47.2 million | $62.8 million |
| Gross Margin | 30.1% | 42.1% | 30.1% | 40.4% |
| Operating Loss | $(36.1) million | $(19.7) million | $(70.7) million | $(39.5) million |
| Net Loss (Attributable to Fulgent) | $(29.5) million | $(19.0) million | $(54.4) million | $(30.5) million |
| Diluted EPS | $(1.05) | $(0.62) | $(1.85) | $(0.99) |
| Cash & Marketable Securities | $257.0 million | N/A | $257.0 million (as of 6/30/26) | $416.1 million (as of 12/31/25) |
| Free Cash Flow (Operating) | $(16.7) million (YTD) | $(34.6) million (YTD) | $(16.7) million | $(34.6) million |
Note: Cash and Marketable Securities calculated as Cash ($26.3M) + Short-term Marketable Securities ($230.7M) + Long-term Marketable Securities ($294.3M) = $551.3M total liquid assets. The table above reflects the sum of Cash and Short-term securities for immediate liquidity context, though total liquid assets are $551.3M.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 4% QoQ and 1% YTD, driven by the Bako Acquisition (adding ~$12.9M in anatomic pathology revenue) and growth in BioPharma services. This was partially offset by a 13% decline in Precision Diagnostics revenue due to a major customer transitioning testing in-house.
- Margin Compression: Gross margin declined from 42% to 30% (Q2) and 40% to 30% (YTD). This was primarily caused by lower collection rates and higher fixed costs associated with the final phase of a new billing and revenue cycle management system implementation, which created processing backlogs.
- Operating Expenses: Operating expenses increased 14% QoQ and 15% YTD. Increases were driven by the Bako Acquisition integration costs, higher selling and marketing spend, and a $2.2 million impairment charge related to intangible assets from the ANP acquisition due to the loss of a significant customer.
- Stock Repurchases: The Company significantly increased buyback activity, repurchasing 4.1 million shares for $63.9 million YTD 2026, compared to 0.6 million shares for $10.9 million YTD 2025.
Guidance, Outlook, and Risks
- Operational Outlook: Management expects collection rates and gross margins to improve as customizations for the new billing system are completed, though exact timing is uncertain. The Bako Acquisition is expected to contribute further to revenue in future periods.
- Therapeutic Pipeline: Updated Phase 2 data for FID-007 showed a 61.9% objective response rate. An End of Phase 2 meeting with the FDA is scheduled for August 2026, with a potential Phase 3 trial commencement in H1 2027.
- Liquidity: The Company holds approximately $551 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months. Approximately $75.8 million remains available under the stock repurchase program.
- Legal & Regulatory Risks: The Company is subject to ongoing investigations by the DOJ (Civil Investigative Demands) and HRSA regarding False Claims Act allegations and COVID-19 reimbursement audits. A qui tam complaint was dismissed without prejudice in February 2026. The Company cannot estimate potential losses from these matters.
- Impairment Risk: While no goodwill impairment was recorded, the Laboratory Services reporting unit's fair value exceeded its carrying value by only 11%, indicating a heightened risk of future impairment if performance targets are not met.
Investor Verification Checklist
- Billing System Transition: Verify the timeline for completing billing system customizations and the projected impact on collection rates and gross margins.
- Customer Concentration: Monitor the revenue decline from the largest customer transitioning to in-house testing and the success of diversification efforts.
- Legal Exposure: Track developments in the DOJ and HRSA investigations regarding False Claims Act and reimbursement audits.
- Goodwill Valuation: Assess the sensitivity of the Laboratory Services goodwill valuation given the narrow 11% margin between fair value and carrying value.
- Therapeutic Milestones: Confirm the outcome of the FDA End of Phase 2 meeting for FID-007 in August 2026.